Steroid receptor ligands for breast cancer targeting: An insight into their potential role as pet imaging agents

Current Medicinal Chemistry

Volumn 20, Issue 2, 2013, Pages 222-245

  Oliveira, M C ^a   Neto, C ^a   Morais, G Ribeiro ^a   Thiemann, T ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Breast cancer; Estradiol; Estrogen receptor; PET imaging; Progesterone; Progesterone receptor; Tumour targeting

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; 16ALPHA, 17ALPHA DIHYDROXYPROGESTERONE ACETOPHENIDE; 21 FLUORO 16ALPHA ETHYL 19 NORPROGESTERONE F18; 4 FLUOROPROPYL TANAPROGET F 18; 6 ALPHA FLUOROPROGESTERONE F 18; CARBON 11; DIFLUORO 11BETA METHOXYESTRADIOL F18; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F18; FLUOROHEXESTROL F18; FLUOROPENTESTROL F18; FLUOROTAMOXIFEN F18; FULVESTRANT F18; GALLIUM 68; IODINE 123; IODINE 124; PROGESTERONE RECEPTOR; RADIOISOTOPE; RADIOLIGAND; STEROID HORMONE; STEROID RECEPTOR; TAMOXIFEN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; FOLLOW UP; HUMAN; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROGNOSIS; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84877994237     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804806658     Document Type: Review

References (320)

1. Veronesi, U.; Boyle, P.; Goldhirsch, A.; Orecchia, R.; Viale, G. Breast cancer. The Lancet, 2005, 365, 1727-1741. (Pubitemid 40719108)
2. Pitot, H.C. The molecular biology of carcinogenesis. Cancer, 1993, 72(S3), 962-970. (Pubitemid 23218011)
3. Beatson, G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, 1896, 2, 104-107.
4. Dodds, E.C.; Golberg, L.; Lawson, W.; Robinson, R. Oestrogenic activity of certain synthetic compounds. Nature, 1938, 141, 247-248.
5. King, R.J.B.; Gordon, J. The localization of [6,7-3H]oestradiol-17in rat uterus. J. Endocr., 1966, 34, 431-437.
6. Stumpf, W.E. Subcellular distribution of 3H-estradiol in rat uterus by quantitative autoradiography: a comparison between 3H-estradiol and 3Hnorethynodrel. Endocrinology, 1968, 83, 777-782.
7. Toft, D.; Gorski, J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA, 1966, 55, 1574-1581.
8. Jensen, E.V.; De Sombre, E.R. Estrogen-receptor interaction. Science, 1973, 182, 126-133.
9. Harper, M.J.K.; Walpole, A.L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature, 1966, 212, 87.
10. McGuire, W.L. Current status of estrogen receptors in human breast cancer. Cancer, 1975, 36, 638-644.
11. Lippman, M.E. Steroid hormone receptors in human malignancy. Life Sci., 1976, 18, 143-152.
12. Lippman, M.E.; Allegra, J.C. Current concepts in cancer. Receptors in breast cancer. New Engl. J. Med., 1978, 299, 930-933. (Pubitemid 9050460)
13. Allegra, J.C.; Lippman, M.E.; Green, L.; Barlock, A.; Simon, R.; Thompson, E.B.; Huff, K.K.; Griffin, W. Estrogen receptor values in patients with benign breast disease. Cancer, 1979, 44, 228-231. (Pubitemid 9234936)
14. Edwards, D.P.; Chamness, G.C.; McGuire, W.L. Estrogen and progesterone receptor proteins in breast cancer. Biochim. Biophys. Acta, 1979, 560, 457-486. (Pubitemid 10167632)
15. Keen, J.C.; Davidson, N.E. The biology of breast carcinoma. Cancer, 2003, 97(S3), 825-833. (Pubitemid 36125819)
16. McGuire, W.L.; Horwitz, K.B.; Pearson, O.H.; Segaloff, A. Current status of estrogen and progesterone receptors in breast cancer. Cancer, 1977, 39, 2934-2947. (Pubitemid 8130407)
17. Sedlacek, S.M.; Horwitz, K.B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids, 1984, 44, 467-484. (Pubitemid 16224031)
18. Horwitz, K.B.; McGuire, W.L.; Pearson, O.H.; Segaloff, A. Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science, 1975, 189, 726-729.
19. Sledge Jr., G.W.; McGuire, W.L. Steroid hormone receptors in human breast cancer. Adv. Cancer Res., 1983, 38, 61-75.
20. Maass, H.; Jonat, W. Steroid receptors as a guide for therapy of primary and metastatic breast cancer. J. Steroid Biochem., 1983, 19, 833-837.
21. Fisher, B.; Fisher, E.R.; Redmond, C.; Brown, A. Tumor nuclear grade, estrogen receptor, and progesterone receptor. Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res. Treat., 1986, 7, 147-160. (Pubitemid 16004881)
22. Brandes, S.J.; Katzenellenbogen, J.A. Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate. Nucl. Med. Biol., 1988, 15, 53-67. (Pubitemid 18013864)
23. Katzenellenbogen, J.A. The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In: The Chemistry and Pharmacology of Radiopharmaceuticals. Nunn, A.D., Ed.; Marcel Dekker: New York, 1992, pp. 297-331.
24. Katzenellenbogen, J.A.; Welch, M.J.; Dehdashti, F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res., 1997, 17, 1573-1576. (Pubitemid 27263124)
25. Bonekamp, D.; Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes & Dev., 2003, 17, 545-580. (Pubitemid 36307540)
26. Bai, M; Bornhop, D.J. Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging. Curr. Med. Chem,. 2012, 4742-4758.
27. Kobayashi, H.; Longmire, M.R.; Ogawa, M.; Choyke P.L. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem. Soc. Rev., 2011, 40, 4626-4648.
28. Bonekamp, D.; Hammoud, D. A.; Pomper, Martin G. Molecular Imaging, Techniques and Current Clinical Applications. Appl Radiology, 2010, 39
29. Eckelman, W.C. In: Radiopharmaceuticals. Chemistry and Pharmacology, Nunn, A. D., Ed.; Marcel Dekker, New York, 1992; Vol. 5, pp. 167-219.
30. Cummins, C.H. Radiolabelled steroidal estrogens in cancer research. Steroids, 1993, 58, 245-259.
31. Welch, M.J.; Downer, J.B.; Katzenellenbogen, J.A. Steroid hormone receptors as targets for diagnostic imaging In: Current Directions in Radiopharmaceutical Research and Development, Mather S. J., Ed., Kluwer Academic Publishers Dordrecht, Boston, London, 1996, p. 137-156.
32. Van de Wiele, C.; De Vos, F.; Slegers, G.; Van Belle, S.; Dierckx, R.A. Radiolabelled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review. Eur. J. Nucl. Med., 2000, 27, 1421-1433.
33. Katzenellenbogen, J.A. In: Handbook of Radiopharmaceuticals. Radiochemistry and Applications, Welch, M. J., Redvanly, C. S., Eds.; John Wiley & Sons, Ltd; Chichester, UK, 2003; Vol. 25, pp 715-750.
34. Van Den Bossche, B.; Van de Wiele, C. Receptor imaging in oncology by means of nuclear medicine: current status. J. Clin. Oncol., 2004, 22, 3593-3607. (Pubitemid 41103667)
35. Oliveira, M.C.; Neto, C.; Gano, L.; Marques, F.; Santos, I.; Thiemann, T.; Santos, A.C.; Botelho, F.; Oliveria, C.F. Estrogen receptor ligands for targeting breast tumours: a brief outlook on radioiodination strategies. Curr. Radiopharm. 2012, 5, 124-141.
36. Bennink, R.J.; van Tienhoven, G.; Rijks, L.J.; Noorduyn, A.L.; Janssen, A.G.; Sloof, G.W. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J. Nucl. Med., 2004, 45, 1-7. (Pubitemid 47611601)
37. Kumar, P.; Mercer, J.; Doerkson, C.; Tonkin, K.; McEwan, A.J.B. Clinical production, stability studies and PET imaging with 16-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J. Pharm. Pharmaceut. Sci., 2007, 10, 256s-265s. (Pubitemid 47082970)
38. Beauregard, J.-M.; Croteau, E.; Ahmed, N.; van Lier, J.E.; Bénard, F. Assessment of human biodistribution and dosimetry of 4-fluoro-11-methoxy-16- 18F-fluoroestradiol using serial whole-body PET/CT. J. Nucl. Med., 2009, 50, 100-107.
39. Dehdashti, F.; Laforest, R.; Gao, F.; Aft, R.L.; Dence, C.S.; Zhou, D.; Shoghi, K.I.; Siegel, B.A.; Katzenellenbogen, J.A.; Welch, M.J. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16,17-[(R)- (1-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J. Nucl. Med., 2012, 53, 363-370.
40. Adam, M.J.; Wilbur, D.S. Radiohalogens for imaging and therapy. Chem. Soc. Rev., 2005, 34, 153-163. (Pubitemid 40311448)
41. Ametamey, S.M.; Honer, M.; Schubiger, P.A. Molecular Imaging with PET. Chem. Rev., 2008, 108, 1501-1516. (Pubitemid 351796395)
42. Miller, P.W.; Long, N.J.; Vilar, R.; Gee A.D. Synthesis of C-11, F-18, O-15, and N-13 radiolabels for positron emission tomography. Angew. Chem. Int. Ed. Engl., 2008, 47, 8998-9033.
43. Li, Z.B.; Conti, P.S. Radiopharmaceutical chemistry for positron emission tomography. Adv. Drug Deliv. Rev., 2010, 62, 1031-1051.
44. Alauddin, M.M; Gelovani, J.G. Pyrimidine nucleosides in molecular PET imaging of tumor proliferation. Curr. Med. Chem., 2010, 17, 1010-1029.
45. Kramer-Marek, G.; Capala, J. Can PET Imaging Facilitate Optimization of Cancer Therapies? Curr. Pharm. Design., 2012, 18, 2657-2669.
46. Landvatter, S.W.; Kiesewetter, D.O.; Kilbourn, M.R.; Katzenellenbogen, J.A.; Welch, M.J. (2R, 3S)-1-[F-18]fluoro-2,3-bis(4-hydroxyphenyl) pentane ([F-18]fluoronorhexestrol), a positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo. Life Sci., 1983, 33, 1933-1938. (Pubitemid 13010945)
47. Bergmann, K.E.; Landvatter, S.W.; Rocque, P.G.; Carlson, K.E.; Welch, M.J.; Katzenellenbogen, J.A. Oxohexestrol derivatives labeled with F-18 -synthesis, receptor-binding and in-vitro distribution of two non-steroidal estrogens as potential breast-tumor imaging agents. Nucl. Med. Biol., 1994, 21, 25-39. (Pubitemid 24037220)
48. Seo, J.W.; Chi, D.Y.; Dence, C.S.; Welch, M.J.; Katzenellenbogen, J.A. Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor. Nucl. Med. Biol., 2007, 34, 383-390. (Pubitemid 46710407)
49. Yang, D.J.; Li, C.; Kim, E.E. Imaging of anti-cancer drug for therapeutics response and prognosis, In: Targeted imaging in oncology. Springer, New York, 2001, pp. 192-199.
50. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science, 1988, 240, 889-895.
51. Katzenellenbogen, J.A.; O'Malley, B.W.; Katzenellenbogen, B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-And promoter-specific action of these hormones. Mol. Endocrinol., 1996, 10, 119-131. (Pubitemid 26042544)
52. Ray, S.; Rastogi, R.; Kumar, A. Current status of estrogen receptors, Prog. Drug Res., 2002, 59, 201-232.
53. Sarrel, P.M.; Lufkin, E.G.; Oursler, M.J.; Keefe, D. Estrogen actions in arteries, bone, and brain. Sci Am Aci Med, 1994, 1, 44-53.
54. Greene, G.L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science, 1986, 231, 1150-1154. (Pubitemid 16016313)
55. Kuiper, G.G.J.M.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA., 1996, 93, 5925-5930. (Pubitemid 26190778)
56. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett., 1996, 392, 49-53. (Pubitemid 26268330)
57. Pearce, S.T.; Jordan, V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol., 2004, 50, 3-22. (Pubitemid 38501614)
58. Speirs, V.; Carder, P. J.; Lane, S.; Dodwell, D.; Lansdown, M.R.J.; Hanby, A.M. Oestrogen receptor : what it means for patients with breast cancer. Lancet Oncol., 2004, 5, 174-181. (Pubitemid 38262850)
59. Clarke, R.B.; Anderson, E., Howell, A. Steroid receptors in human breast cancer. Trends Endocrinol. Metab., 2004, 15, 316-23. (Pubitemid 39180006)
60. Balfe, P.J.; McCann, A.H.; Welch, H.M.; Kerin, M.J. Estrogen receptor beta and breast cancer. Eur. J. Surg. Oncol., 2004, 30, 1043-1050. (Pubitemid 40267807)
61. Kumar, V.; Green, S.; Staub, A.; Chambon, P. Localisation of the oestradiolbinding and putative DNA-binding domains of the human oestrogen receptor. EMBO J., 1986, 5, 2231-2236.
62. Kumar, V.; Green, S.; Stack, G.; Berry, M.; Jin, J.R.; Chambon P. Functional domains of the human estrogen receptor. Cell, 1987, 51, 941-951.
63. Menasce, L.P.; White, G.R.; Harrison, C.J.; Boyle, J.M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics, 1993, 17, 263-265. (Pubitemid 23205095)
64. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustaffson, J.A. Human estrogen receptor beta-gene structure, chromosomal location, and expression pattern. J. Clin. Endocrinol. Metab., 1997, 82, 4258-4265. (Pubitemid 27525550)
65. Ogawa, S.; Inoue, S.; Watanabe, T.; Hiroi, H.; Orimo, A.; Hosoi, T.; Ouchi, Y.; Muramatsu, M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun., 1998, 243, 122-126. (Pubitemid 28414201)
66. Kuiper, G.G.J.M.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustaffson, J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor and . Endocrinology, 1997, 138, 863-870. (Pubitemid 27089735)
67. Hall, J.M.; McDonnell, D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 1999, 140, 5566-5578. (Pubitemid 30645344)
68. Fawell, S.E.; Lees, J.A.; White, R.; Parker, M.G. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell, 1990, 60, 953-962.
69. Danielian, P.S.; White, R.; Lees, J.A.; Parker, M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J., 1992, 11, 1025-1033.
70. Wrenn, C.K.; Katzenellenbogen, B.S. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem., 1993, 268, 24089-24098. (Pubitemid 23335391)
71. Krust, A.; Green, S.; Argos, P.; Kumar, V.; Walter, P.; Bornert, J.M.; Chambon, P. The chicken oestrogen receptor sequence: homology with verbA and the human oestrogen and glucocorticoid receptors. EMBO J., 1986, 5, 891-897.
72. Tora, L.; White, J.H.; Brou, C.; Tasset, D.; Webster, D.; Scheer, E.; Chambon, P. The human estrogen receptor has two independent non-Acidic trancriptional activation functions. Cell, 1989, 59, 477-487. (Pubitemid 19284461)
73. Kraus, W.L.; McInerney, E.M.; Katzenellenbogen, B.S. Ligand-dependent, transcriptionally productive association of the amino-And carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. U.S.A., 1968, 92, 12314-12318.
74. McInerney, E.M.; Katzenellenbogen, B.S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-And estradiol-dependent transcription activation. J. Biol. Chem., 1996, 271, 24172-24178. (Pubitemid 26327401)
75. Shiau, A.K.; Barstad, D.; Loria, P.M.; Cheng, L.; Kushner, P.J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 1998, 95, 927-937. (Pubitemid 29019045)
76. Pike, A.C.W.; Brzozowski, A.M.; Hubbard, R.E.; Bonn, T.; Thorsell, A.-G.; Engstrom, O.; Ljunggren, J.; Gustaffson, J.A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J., 1999, 18, 4608-4618. (Pubitemid 29415516)
77. Kumar, V.; Chambon, P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell, 1988, 55, 145-156.
78. McDonnell, D.P.; Nawaz, Z.; O'Malley, B.W. In situ distinction between steroid receptor binding and transactivation at a target gene. Mol. Cell Biol., 1991, 11, 4350-4355. (Pubitemid 21895828)
79. Elliston, J.F.; Fawell, S.E.; Klein-Hitpass, L.; Tsai, S.Y.; Tsai, M.J.; Parker, M.G.; O'Malley, B.W. Mechanism of estrogen receptor-dependent transcription in a cell-free system. Mol. Cell Biol., 1990, 10, 6607-6612. (Pubitemid 120004604)
80. Edwards, D. Coregulatory proteins in steroid hormone receptor action. Vitam. Horm., 1999, 55, 165-218.
81. Glass, C.K.; Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev., 2000, 14, 121-141. (Pubitemid 30070977)
82. McKenna, N.J.; O'Malley, B.W. Combinational control of gene expression by nuclear receptors and coregulators. Cell, 2002, 108, 465-474. (Pubitemid 34260872)
83. Milgrom, E.; Baulieu, E.-E. Progesterone in uterus and plasma. I. Binding in rat uterus 105,000 g supernatant. Endocrinology, 1970, 87, 276-286.
84. Milgrom, E.; Atger, M.; Baulieu, E.-E. Progesterone in uterus and plasma. IV-Progesterone receptor(s) in guinea pig uterus cytosol. Steroids, 1970, 16, 741-754.
85. Sherman, M.R.; Corvol, P.L.; O'Malley, B.W. Progesterone-binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. J. Biol. Chem., 1970, 245, 6085-6096.
86. Leavitt, W.W.; Blaha, G.C. An estrogen-stimulated, progesterone-binding system in the hamster uterus and vagina. Steroids, 1972, 19, 263-274.
87. Giangrande, P.H.; McDonnell, D.P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog. Horm. Res., 1999, 54, 291-313.
88. Keen, J.C.; Davidson, N.E. The biology of breast carcinoma. Cancer, 2003, 97, 825-33. (Pubitemid 36125819)
89. Mote, P.A.;. Bartow, S.; Tran N.; Clarke, C.L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat., 2002, 72, 163-172. (Pubitemid 34407211)
90. Tsai, M.-J.; O'Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem., 1994, 63, 451-486. (Pubitemid 24218640)
91. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R.M. The nuclear receptor superfamily: the second decade. Cell, 1995, 83, 835-839.
92. Lu, N.Z.; Wardell, S.E.; Burnstein, K.L.; Defranco, D.; Fuller, P.J.; Giguere, V.; Hochberg, R.B.; McKay, L.; Renoir, J.M.; Weigel, N.L.; Wilson, E.M.; McDonnell, D.P.; Cidlowski, J.A. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev., 2006, 58, 782-797. (Pubitemid 44833746)
93. Georgiakaki, M.; Chabbert-Buffet, N.; Dasen, B.; Meduri, G.; Wenk, S.; Rajhi, L.; Amazit, L.; Chauchereau, A.; Burger, C.W.; Blok, L.J.; Milgrom, E.; Lombes, M.; Guiochon-Mantel, A.; Loosfelt, H. Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol. Endocrinol., 2006, 20, 2122-2140. (Pubitemid 44286709)
94. Padhani, A.R.; Krohn, K.A.; Lewis, J.S.; Alber, M. Imaging oxygenation of human tumours. Eur. Radiol., 2007, 17, 861-872. (Pubitemid 46772763)
95. Riemann, B.; Schafers, K.P.; Schober, O.; Schafers, M. Small animal PET in preclinical studies: opportunities and challenges. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 215-221.
96. Dunphy, M.P.S.; Lewis, J.S. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J. Nucl. Med., 2009, 50, 106s-121s.
97. Koukourakis, G.; Maravelis, G.; Koukouraki, S.; Padelakos, P.; Kouloulias, V. Overview of positron emission tomography chemistry: clinical and technical considerations and combination with computed tomography. J. Buon., 2009, 14, 575-580.
98. Anderson, C.J.; Bulte, J.W.M.; Chen, K.; Chen, X.; Khaw, B.-A.; Shokeen, M.; Wooley, K.L.; VanBrocklin, H.F. Design of targeted cardiovascular molecular imaging probes. J. Nucl. Med., 2010, 51, 3S-17S.
99. Xiong, K.L.; Yang, Q.W.; Gong, S.G.; Zhang, W.G. The role of positron emission tomography imaging of beta-Amyloid in patients with Alzheimer's disease. Nucl. Med. Commun., 2010, 31, 4-11.
100. Hallett, W.A.; Maguire, R.P.; McCarthy, T.J.; Schmidt, M.E; Young, H. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development. Idrugs, 2007, 10, 791-796. (Pubitemid 350034525)
101. Murphy, P.S.; McCarthy, T.J.; Dzik-Jurasz, A.S.K. The role of clinical imaging in oncological drug development. Br. J. Radiol., 2008, 81, 685-692.
102. Takano, A. The Application of PET Technique for the Development and Evaluation of Novel Antipsychotics. Curr. Pharm. Des., 2010, 16, 371-377.
103. Beyer, T.; Townsend, D.W.; Brun, T.; Kinahan, P.E.; Charron, M.; Roddy, R; Jerin, J. Young, J.; Byars, L.; Nutt, R. A combined PET/CT scanner for clinical oncology. J. Nucl. Med., 2000, 41, 1369-1379. (Pubitemid 30643379)
104. Townsend, D.W.; Cherry, S.R. Combining anatomy and function: the path to true image fusion. Eur. Radiol., 2001, 11, 1968-1974. (Pubitemid 32936900)
105. Blodgett, T.M.; Meltzer, C.C.; Townsend, D.W. PET/CT: Form and function. Radiology, 2007, 242, 360-385. (Pubitemid 46150968)
106. Kilbourn, M.R. Fluorine-18 labeling of radiopharmaceuticals, Nuclear Science Series NAS-NS-3203, Washington DC: National Academy Press, 1990.
107. Coenen, H.H. PET Radiopharmaceuticals; fluorinated compounds. In: Von Schulthess G, Ed. Clinical molecular anatomic imaging. Lippincott Williams & Wilkins, Philadelphia, 2003, pp. 106-114.
108. Coenen, H.H. Fluorine-18 labeling methods: features and possibilities of basic reactions. In: Schubiger, P.A., Lehmann, L., Friebe, M., Eds. Ernst Schering Research Foundation Workshop 62 PET Chemistry The Driving Force in Molecular Imaging, 2007.
109. Stocklin, G. Molecules labeled with positron emitting halogens. Nucl. Med. Biol., 1986, 13, 109-118. (Pubitemid 16018304)
110. Moerlein, S.M.; Laufer, P.; Stocklin, G.; Pawlik, G.; Wienhard, K.; Heiss, W.-D. Evaluation of Br-75 labeled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography. Eur. J. Nucl. Med., 1986, 12, 211-216. (Pubitemid 16009565)
111. Mathis, C.A.; Sargent, T.A.; Shulgin, A.T.; Yano, Y.; Budinger, T.F.; Lagunas-Solar, M.C. Synthesis and evaluation of meta-substituted I-122-labeled dimethoxy-N,N-dimethylamphetamines for brain imaging studies. J. Nucl. Med., 1985, 26, P69.
112. Mathis, C.A.; Lagunas-Solar, M.C.; Sargent, T.A; Yano, Y.; Vuletich, A.; Harris, L.J. Xe-122 I-122 generator for remote radio-iodinations. Appl. Rad. Isotop., 1986, 37, 258-260.
113. Koehler, L.; Gagnon, K.; McQuarrie, S.; Wuest, F. Iodine-124: A promising positron emitter for organic PET chemistry. Molecules, 2010, 15, 2686-2718.
114. Ehrenkaufer, R.E.; Potocki, J.F.; Jewett, D.M. Synthesis of F-18-labeled 2-fluoro-2-deoxy-D-glucose: concise communication. J. Nucl. Med., 1984, 25, 333-337. (Pubitemid 14152920)
115. Pauwels, E.K.J.; Ribeiro, M.J.; Stoot, J.H.M.B.; McCready, V.R.; Bourguignon, M.; Maziére, B. FDG accumulation and tumor biology. Nucl. Med. Biol., 1998, 25, 317-322. (Pubitemid 28219093)
116. Bolton, R. Radiohalogen incorporation into organic systems. J. Labelled Compd. Radiopharm., 2002, 45, 485-528. (Pubitemid 34587075)
117. Coenen, H.H.; Schuller, M.; Stocklin, G.; Klatte, B.; Knochel, A. Preparation of Nca [17-F-18]-fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination. J. Labelled Compd. Radiopharm., 1986, 23, 455-466. (Pubitemid 16116556)
118. Hamacher, K.; Coenen, H.H.; Stocklin, G. Efficient stereospecific synthesis of no-carrier-Added 2-[F-18]-fluoro-2-deoxy-D-glucose using aminopoly ether supported nucleophilic substitution. J. Nucl. Med., 1986, 27, 235-238. (Pubitemid 17024868)
119. Kiesewetter, D.O., Kilbourn, M.R., Landvatter, S.W., Heiman, D.F., Katzenellenbogen, J.A., Welch, M.J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med., 1984, 25, 1212-1221. (Pubitemid 15214135)
120. Angeli, G.; Speranza, M.; Wolf, A.P.; Shiue, C.Y.; Fowler, J.S.; Watanabe, M. New developments in the synthesis of no-carrier added (nca) 18F-labeled aryl fluoride using nucleophilic substitution reaction. J. Labelled Compd. Radiopharm., 1984, 21, 1223-1225.
121. Coenen, H.H. No-carrier-Added 18F-chemistry of radiopharmaceuticals. In: Baille, T.A.; Jones, J.R., Eds.; Synthesis and application of isotopically labeled compounds; Elsevier: Amsterdam, 1989, pp. 433-448.
122. Koren, A.O.; Horti, A.G.; Mukhin, A.G; Gundisch, D.; Dannals, R.F.; London, E.D. Synthesis and initial in vitro characterization of 6-[F-18]fluoro-3-(2(S)-Azetidinylmethoxy)pyridine, a high-Affinity radioligand for central nicotinic acetylcholine receptors. J. Labelled Compd. Radiopharm., 2000, 43, 413-423. (Pubitemid 30204176)
123. Sandell, J.; Halldin, C.; Pike, V.W.; Chou, Y.H.; Varnas, K.; Hall, H.; Marchais, S.; Nowicki, B.; Wikstrom, H.V.; Swahn, C.G.; Farde, L. New halogenated [C-11]WAY analogues, [C-11]6FPWAY and [C-11]6BPWAY -Radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey. Nucl. Med. Biol. 2001, 28, 177-185. (Pubitemid 32276082)
124. Karramkam, M.; Hinnen, F.; Berrehouma, M.; Hlavacek, C.; Vaufrey, F.; Halldin, C.; McCarron, J.A.; Pike, V.W.; Dolle, F. Synthesis of a [6-pyridinyl-F-18]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. Bioorg. Med. Chem., 2003, 11, 2769-2782. (Pubitemid 36683001)
125. Dolle, F. Fluorine-18-labelled fluoropyridines: advances in radiopharma ceutical design. Curr. Pharm. Des., 2005, 11, 3221-3235. (Pubitemid 41300773)
126. Cai, L.S.; Lu, S.Y., Pike, V.W. Chemistry with [F-18]fluoride ion. Eur. J. Org. Chem., 2008, 2853-2873.
127. Pike, V.W.; Butt, F.; Shah, A.; Widdowson, D.A. Facile synthesis of substituted diaryliodonium tosylates by treatment of aryltributylstannanes with Koser's reagent. J. Chem. Soc., Perkin Trans. 1, 1999, 245-248.
128. Ross, T.L.; Ermert, J.; Hocke, C.; Coenen, H.H. Nucleophilic F-18-Fluorination of heteroaromatic iodonium salts with no-carrier-Added [F-18]Fluoride. J. Am. Chem. Soc., 2007, 129, 8018-8025. (Pubitemid 46998201)
129. Ermert, J.; Hocke, C.; Ludwig, T.; Gail, R.; Coenen, H.H. Comparison of pathways to the versatile synthon of no-carrier-Added 1-bromo-4-[F-18] fluorobenzene. J. Labelled Compd. Radiopharm., 2004, 47, 429-441. (Pubitemid 38915440)
130. Wust, F.; Carlson, K.E.; Katzenellenbogen, J.A. Synthesis of novel arylpyrazolo corticosteroids as potential ligands for imaging brain glucocorticoid receptors. Steroids, 2003, 68, 177-191. (Pubitemid 36279169)
131. Guhlke, S.; Coenen, H.H.; Stöcklin, G. Fluoroacylation agents based on small n.c.a[18F]fluorocarboxylic acids. Appl. Radiat. Isotop., 1994, 45, 715-727.
132. Kilbourn, M.R.; Dence, C.S.; Welch, M.J.; Mathias, C.J. Fluorine-18 labeling of proteins. J. Nucl. Med., 1987, 28, 462-470. (Pubitemid 17074168)
133. Block, D.; Coenen, H.H.; Stöcklin, G. N.C.A. 18F-fluoroalkylation of Hacidic compounds. J. Labelled Compd. Radiopharm., 1988, 25, 201-216.
134. Jacobson, K.A.; Furlano, D.C.; Kirk, K.L. A prosthetic group for the rapid introduction of fluorine into peptides and functionalized drugs. J. Fluor. Chem., 1988, 39, 339-347.
135. Shai, Y.; Kirk, K.L.; Channing, M.A.; Dunn, B. B.; Lesniak, M.A.; Eastman, R.C.; Finn, R.D.; Roth, J.; Jacobson, K.A. Fluorine-18 labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. Biochemistry, 1989, 28, 4801-4806. (Pubitemid 19151060)
136. Hostetler, E.D; Edwards, W.B.; Anderson, C.J.; Welch, M.J. Synthesis of 4-[18F]fluorobenzoyl octreotide and biodistribution in tumor-bearing lewis rats. J. Labelled Compd. Radiopharm., 1999, 42(Suppl. 1), S720-S721.
137. Lang, L.X.; Eckelman, W.C. One-step synthesis of 18F labeled [18F]-Nsuccinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl. Radiat. Isotop., 1994, 45, 1155-1163.
138. Vaidyanathan, G.; Zalutsky, M.R. Improved synthesis of N-succinimidyl 4- [18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjugate Chem., 1994, 5, 352-356.
139. Dolle, F.; Hinnen, F.; Vaufrey, F.; Tavitian, B.; Crouzel, C. A general method for labeling oligodeoxynucleotides with 18F for in vivo PET imaging. J. Labelled Compd. Radiopharm., 1997, 39, 319-330. (Pubitemid 27149924)
140. Poethko, T.; Schottelius, M.; Thumshim, G.; Hersel, U.; Herz, M.; Henriksen, G.; Kessler, H.; Schwaiger, M.; Wester, H.J. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs, J. Nucl. Med., 2004, 45, 892-902. (Pubitemid 47618571)
141. Glaser, M.; Karlsen, H.; Solbakken, M.; Arukwe, J.; Brady, F.; Luthra, S.K.; Cuthbertson, A. 18F-Fluorothiols: a new approach to label peptides chemoselectively as potential tracers for positron emission tomography. Bioconjugate Chem., 2004, 15, 1447-1453. (Pubitemid 39552036)
142. Wester, H.J.; Hamacher, K.; Stöcklin, G. A comparative study of N.C.A. Fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl. Med. Biol., 1996, 23, 365-372. (Pubitemid 26164971)
143. Okarvi, S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur. J. Nucl. Med., 2001, 28, 929-938. (Pubitemid 32663907)
144. Marik, J.; Sutcliffe, J.L. Click for PET: rapid preparation of [18F] fluoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett., 2006, 47, 6681-6884.
145. Tang, L. Radionuclide production and yields at Washington University School of Medicine. Q. J. Nucl. Med. Mol. Imag., 2008, 52, 121-133. (Pubitemid 351721931)
146. Lang, L.; Li, W.; Jia, H.-M.; Fang, D.-C.; Zhang, S.; Sun, X.; Zhu, L.; Ma, Y.; Shen, B.; Kiesewetter, D.O.; Niu, G.; Chen, X. New methods for labeling RGD peptides with bromine-76. Theranostics, 2011, 1, 341-353.
147. McElvany, K.D.; Welch, M.J. Characterization of bromine-77-labeled proteins prepared using bromoperoxidase. J. Nucl. Med., 1980, 21, 953-960. (Pubitemid 10010842)
148. Sundin, J.; Tolmachev, V.; Koziorowski, J.; Carlsson, J.; Lundqvist, H.; Welt, S.; Larson, S.; Sundin, A. High yield direct Br-76-bromination of monoclonal antibodies using chloramine-T. Nucl. Med. Biol., 1999, 26, 923-929. (Pubitemid 30047162)
149. Knight, L.C.; Harwig, S.S.L.; Welch, M.J. In vitro stability and in vivo clearance of fibrinogen or serum-Albumin labeled with Br-77, I-131, or I-125 by direct or indirect synthetic methods. J. Nucl. Med., 1977, 18, 282-288. (Pubitemid 8058298)
150. Hoglund, J.; Tolmachev, V.; Orlova, A.; Lundqvist, H; Sundin, A. Optimized indirect Br-76-bromination of antibodies using N-succinimidyl para-[Br-76]bromobenzoate for radioimmuno PET. Nucl. Med. Biol., 2000, 27, 837-843. (Pubitemid 32058823)
151. Zhou, D.; Sharp, T.L.; Fettig, N.M.; Lee, H.; Lewis, J.S.; Katzenellenbogen, J.A.; Welch, M.J. Evaluation of a bromine-76-labeled progestin 16-Alpha,17-Alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. Nucl. Med. Biol., 2008, 35, 655-663.
152. Elsinga, P.H. Radiopharmaceutical chemistry for positron emission tomo graphy. Methods, 2007, 27, 208-217.
153. Andersson, J.D.; Varnas, H.; Cselenyi, Z.; Guylas, B.; Wensbo, D.; Finnema, S.J.; Swahn, B.M.; Svensson, S.; Nyberg, S.; Farde, L.; Halldin, C. Radiosynthesis of the candidate beta-Amyloid radioligand [C-11]AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse, 2010, 64, 733-741.
154. Jewett, D.M. A Simple synthesis of [C-11] methyl triflate. Appl Rad Isotop. 1992, 43, 1383-1385.
155. Link, J.M.; Krohn, K.A.; Clark, J.C. Production of [C-11]CH3I by single pass reaction of [C-11]CH4 with I-2. Nucl. Med. Biol., 1997, 24, 93-97.
156. Larsen, P.; Ulin, J.; Dahlstrom, K.; Jensen M. Synthesis of [C-11]iodomethane by iodination of [C-11]methane. Appl Rad Isotop., 1997, 48, 153-157.
157. Oberdorfer, F.; Hanisch, M.; Helus, F.; Maier-Borst, W. A new procedure for the preparation of 11C-labelled methyl iodide. Appl. Rad. Isotop., 1985, 36, 435-438. (Pubitemid 15065526)
158. Holschbach, M.; Schüller, M. A new and simple on-line method for the preparation of n.c.a. [11C]methyl iodide. Appl. Rad. Isotop., 1993, 44, 779-780. (Pubitemid 23089951)
159. Buckley, K.R.; Jivan, S.; Ruth, T.J. Improved yields for the in situ production of [11C]CH4 using a niobium target chamber. Nucl. Med. Biol., 2004, 31, 825-827 (Pubitemid 38887767)
160. Beauregard, J.-M.; Turcotte, E.; Bénard, F. Steroid receptor imaging in breast cancer. PET Clin., 2006, 1, 51-70.
161. Kumar, R. Targeted functional imaging in breast cancer. Eur J Nucl Med Mol Imaging, 2007, 34, 346-353. (Pubitemid 46295359)
162. de Vries, E.F.J.; Rots, M.G.; Hospers, G.A.P. Nuclear Imaging of Hormonal receptor status in breast cancer: A tool for guiding endocrine treatment and drug development. Curr. Cancer Drug Targets, 2007, 7, 510-519. (Pubitemid 47358139)
163. Hanson, R.N. Preparation of radiohalogenated biomolecules via organotin intermediates. In: Buncel, E.; Jones, J.R., Eds., Isotopes in the physical and biomedical sciences Vol I, Labelled Compounds (Part B), Elsevier, Amsterdam, 1991, pp. 285-340.
164. Bénard, F.; Turcotte, E. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res., 2005, 7, 153-162. (Pubitemid 40872778)
165. Schwartz, J.A.; Skafar, D.F. Ligand mediated modulation of estrogen receptor conformation by estradiol analogs. Biochemistry, 1993, 32, 10109-10115. (Pubitemid 23312439)
166. Raynaud, J.P.; Ojasoo, T. The design and use of sex-steroid antagonists. J. Steroid Biochem., 1986, 25, 811-833. (Pubitemid 17227962)
167. VanBrocklin, H.F; Carlson, K.E; Katzenellenbogen, J.A.; Welch, M.J. 16-([18F]Fluoro)estrogens: systematic investigation of a new series of fluorine-18-labelled estrogens as potential imaging agents for estrogen-receptorpositive breast tumours. J. Med. Chem., 1993, 36, 1619-1629 and references cited therein. (Pubitemid 23180626)
168. Mintun, M.A.; Welch, M.J.; Siegel, B.A.; Mathias, C.J.; Brodack, J.W.; McGuire, A.H.; Katzenellenbogen, J.A. Breast cancer: PET imaging of estrogen receptors. Radiology, 1988, 169, 45-48.
169. Preston, D.F.; Spicer, J.A.; Baranvzuk, C.; Fabian, K.G.; Baxter, N.L.; Martin, R.; Robinson, G. Clinical results of breast cancer detection by imageable estradiol (I-123 E2). Eur. J. Nucl. Med., 1990, A159, 430-430.
170. McGuire, A.H.; Dehdashti, F.; Siegel, B.A.; Lyss, A.P.; Brodack, W.; Mathias, C.J.; Mintun, M.A.; Katzenellenbogen, J.A. Positron tomographic assessment of 16-[18F]Fluoro-17-estradiol uptake in metastatic breast carcinoma. J. Nucl. Med., 1991, 32, 1526-1531.
171. Ribeiro-Barras, M.J.; Foulon, C.; Baulieu, J.L.; Guilloteau, D.; Bougnoux, P.; Lansac, J.; Besnard, J.C. Estrogen receptor imaging with 17-[123I]iodovinyl-11-methoxyestradiol (MIVE2)-part II. Preliminary results in patients with breast carcinoma. Nucl. Med. Biol., 1992, 19, 263-267.
172. Kenady, D.E.; Pavlik, E.J.; Nelson, K.; van Nagell, J.R.; Gallion, H.; De-Priest, P.D.; Ryo, U.Y.; Baranczuk, R.J. Images of estrogen receptor-positive breast tumors produced by estradiol labelled with iodine I-123 at 16. Arch. Surg., 1993, 128, 1373-1381. (Pubitemid 23360033)
173. Hoyte, R.M.; Rosner, W.; Johnson, I.S.; Zielinski, J.; Hochberg, R.B. Synthesis and evaluation of potential radioligands for the progesterone receptor. J. Med. Chem., 1986, 28, 1695-1699.
174. Brandes, S.J.; Katzenellenbogen, J.A. Fluorinated androgens and progestins: Molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol. Pharmacol., 1987, 32, 391-403. (Pubitemid 18007295)
175. Pomper, M.G.; Katzenellenbogen, J.A.; Welch, M.J.; Brodack, J.W.; Mathias, C.J. 21-[18FlFluoro-16-ethyl-19-norprogesterone: Synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J. Med. Chem., 1988, 31, 1360-1363.
176. Pomper, M.G.; Pinney, K.G.; Carlson, K.E.; VanBrocklin, H.; Mathias, C.J.; Welch, M.J.; Katzenellenbogen, J.A. Target tissue uptake selectivity of three fluorine substituted progestins: Potential imaging agents for receptor positive breast tumors. Nucl. Med. Biol., 1990, 17, 309-319. (Pubitemid 20110119)
177. Dedashti, F.; McGuire, A. M.; VanBrocklin, H. F.; Siegel, B.A.; Andriole, D. P Griffeth, L. K.; Pomper, M. G.; Katzenellenbogen, J. A.; Welch, M. J. Assessment of 21-[18Flfluoro-16-ethyl-19-norprogesterone as a positronemitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J. Nucl. Med., 1991, 32, 1532-1537.
178. Verhagen, A.; Studeny, M.; Luurtsema, G.; Vissar, G.M.; de Goeij, C.C.J.; Sluyser, M.; Nieweg, O.E.; Van der Ploeg, E.; Go, K.G.; Vaalburg, W. Metabolism of a [18F]fluorine labeled progestin (21-[18Flfluoro-16a-ethyl-19- norprogesterone) in humans: a clue for future investigations. Nucl. Med. Biol., 1994, 21, 941-952.
179. Anstead, G.M.; Carlson, K.E.; Katzenellenbogen, J.A. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids, 1997, 62, 268-303. (Pubitemid 27114399)
180. Hylarides M.D.; Duesler E.N.; Mettler F.A.; Leon A.A. Structural comparison of l-bromo-And 1-fluoroestradiol with D-estradiol. Acta Crystallog., 1988, C44, 709-712
181. Ali, H.; Rousseau, J.; Gantchev, T.G.; van Lier, J.E. 2-And 4-Fluorinated 16-[125I]iodoestradiol derivatives: synthesis and effect on estrogen receptor binding and receptor-mediated target tissue uptake. J. Med. Chem., 1993, 36, 4255-4263. (Pubitemid 24037937)
182. Ali, H.; Rousseau, J.; van Lier, J.E. Synthesis of A-ring fluorinated derivatives of (17,20E/Z)-[125I]iodovinylestradiols: effect on receptor binding and receptor-mediated target tissue uptake. J. Med. Chem., 1993, 36, 3061-3072. (Pubitemid 23326258)
183. Arunachalam, T.; Longcope, C.; Caspi, E. Iodoestrogens, synthesis, and interaction with uterine receptors. J. Biol. Chem., 1979, 254, 5900-5905. (Pubitemid 9245820)
184. Longcope, C.; Rafkind, I.; Arunachalam, T.; Caspi, E. Biological activities of 4-fluoroestrogen analogs. J. Steroid Biochem., 1983, 19, 1325-1328.
185. Heiman, D.F.; Senderoff, S.G.; Katzenellenbogen, J.A.; Neely, R.J. Estrogen receptor based imaging agents. 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens. J. Med. Chem. 1980, 23, 994-1002. (Pubitemid 11170631)
186. Bucourt, R.; Vignau, M.; Torelli, V.; Richard-Foy, H.; Geynet, C.; Secco-Millet, C.; Redeuilh, G.; Baulieu, E.E. New biospecific adsorbents for the purification of estradiol receptor. J. Biol. Chem., 1978, 253, 8221-8228. (Pubitemid 9073721)
187. Ratajczak, T.; Shepard, P.N.; Capon, R.J.; Hähnel, R. The synthesis and study of some potential affinity labelling reagents for estrogen receptors. Steroids, 1981, 38, 537-555.
188. Weatherill, P.J.; Wilson, A.P.M.; Nicholson, R.I.; Davies, P.; Wakeling, A.E. Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor. J. Steroid. Biochem., 1988, 30, 263-266.
189. Bowler, J.; Lilley, T.J.; Pittam, J.D.; Wakeling, A.E. Novel steroidal pure antiestrogens. Steroids, 1989, 54, 71-99. (Pubitemid 19242474)
190. DaSilva, J.N.; van Lier, J.E. In vivo evaluation of 7-[11-(4- [125I]iodophenoxy)undecyl]-17-estradiol: a potential vector for therapy of adrenal and estrogen receptor-positive cancers. J. Steroid. Biochem. Molec. Biol., 1990, 37, 77-83. (Pubitemid 20385639)
191. Wakeling, A. E.; Bowler, J. ICI 182,780, a new antioestrogen with clinical potential. J. Steroid. Biochem., 1992, 43, 173-177.
192. French, A.N.; Wilson, S.R.; Welch, M.J.; Katzenellenbogen, J.A. A synthesis of 7-substituted estradiols: synthesis and biological evaluation of a 7-pentyl-substituted BODIPY fluorescent conjugate and a fluorine-18-labeled 7-pentylestradiol analog. Steroids, 1993, 58, 157-169.
193. Peters, R.H.; Crowe, D.F.; Avery, M.A.; Chong, W.K.M.; Tanabe, M. 11-nitrate estrane analogues: potent estrogens. J. Med. Chem., 1989, 32, 2306-2310. (Pubitemid 19245892)
194. Bindal, R.D.; Carlson, K.E.; Reiner, G.C.A.; Katzenellenbogen, J.A. 11-chloromethyl-[3H]estradiol-17: a very high affinity, reversible ligand for the estrogen receptor. J. Steroid Biochem. 1987, 28, 361-370.
195. Pomper, M.G.; Vanbrocklin, H.; Thieme, A.M.; Thomas, R.D.; Kiesewetter, D.O.; Carlson, K.E.; Mathias, C.J.; Welch, M.J.; Katzenellenbogen, J.A. 11-Methoxy-, 11-ethyl-And 17-ethynyl-substituted 16-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J. Med. Chem., 1990, 33, 3143-3155.
196. Napolitano, E.; Fiaschi, C.K.E.; Katzenellenbogen, J.A. 11-substituted estradiol derivatives, potential high affinity carbon-11-labelled probes for the estrogen receptor: a structure-Affinity relationship study. J. Med. Chem., 1995, 38, 2774-2779.
197. Ali, H.; Rousseau, J.; Van Lier, J.E. 7-Methyl and 11-ethoxy-substitution of [125I]-16-Iodoestradiol: Effect on estrogen receptor-mediated target tissue uptake. J. Med. Chem., 1993, 36, 264-271. (Pubitemid 23060095)
198. VanBrocklin, H. F.; Liu, A.; Welch, M.J.; O'Neil, J.P.; Katzenellenbogen, J. A. The synthesis of 7-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids, 1994, 59, 34-45.
199. Ojasoo, T.; Raynaud, J.P.; Mornon, J.P. In:Comprehensive Medicinal Chemistry, Steroid Hormone Receptors , Emmet, J.C., Ed. Pergamon Press, New York, 1990, Vol 3, pp. 1175-1226.
200. Vessiéres, A.; Top, S., Vaillant, C.; Osella, D.; Mornon, J.-P.; Jaouen, G. Estradiols modified by metal carbonyl clusters as suicide substrates for the study of receptor proteins: application to the estradiol receptor. Angew. Chem. Int. Ed. Engl., 1992, 31, 753-755.
201. El Amouri, H.; Vessiéres, A.; Vichard, D.; Top, S.; Gruselle, M.; Jaouen, G. Syntheses and affinities of novel organometallic-labelled estradiol derivatives: A structure-Affinity relationship. J. Med. Chem., 1992, 35, 3130-3135.
202. Jaouen, G.; Vessiéres, A. Bioorganometallic chemistry: a future direction for transition metal organometallic chemistry? Acc. Chem. Res., 1993, 26, 361-369.
203. Korenman, S. G. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids, 1969, 13, 163-177.
204. Mazaitis, J.K.; Gibson R.E.; Komai, T.; Eckelman, W.C.; Francis, B.; Reba, R.C. Radioiodinated Estrogen Derivatives. J Nucl. Med., 1980, 21, 142-146. (Pubitemid 10102465)
205. Ali, H.; Rousseau, J.; Ghaffari, M.A.; Van Lier, J.E. Synthesis, receptor binding, and tissue distribution of (17,20E)-And (17,20Z)-21-[125I]Iodo-19- norpregna-1,3,5(10),20-tetraene-3,17-diol. J. Med. Chem., 1988, 31, 1946-1950.
206. Napolitano, E.; Fiaschi, R.; Hanson, R.N. Structure-Activity relationships of estrogenic ligands: synthesis and evaluation of (17,20E)-And (17,20Z)-21-halo-19-norpregna-1,3,5(10),20-tetraene-3,17-diols. J. Med. Chem., 1991, 34, 2754-2759.
207. Ali, H.; Rousseau, J.; van Lier, J.E. Synthesis, receptor binding and biodistribution of the gem-21-chloro-21-iodovinylestradiol derivatives. J. Steroid Biochem. Mol. Biol. 1993, 46, 613-622. (Pubitemid 23346145)
208. Napolitano, E.; Fiaschi, R.; Herman, L. W.; Hanson, R.N. Synthesis and probes for the estrogen receptor binding of (17,20E)-And (17,20Z)-21-phenylthio- 19-norpregna-1,3,5(10),20-tetraene-3,17-diols. Steroids, 1996, 61, 384-389.
209. Neto, C.; Oliveira, M.C.; Gano, L.; Marques, F.; Santos, I.; Ribeiro Morais, G.; Yasuda, T.; Thiemann, T.; Botelho, F.; Oliveira, C.F. Radioiodinated ligands for the estrogen receptor: Effect of different 7-cyanoalkyl chains on the binding affinity of novel iodovinyl-6-dehydroestradiols. Appl. Radiat. Isotop., 2009, 67, 301-307.
210. Neto, C.; Oliveira, M.C.; Gano, L.; Marques, F.; Santos, I.; Ribeiro Morais, G.; Yasuda, T.; Thiemann, T.; Botelho, F.; Oliveira, C.F. Evaluation of novel radioiodinated C7-substituted 6,7-estradiol derivatives for molecular recognition of ER-positive breast tumours. Current Radiopharm., 2009, 2, 83-91.
211. Nakatsuka, I.; Ferreira, N.L.; Eckelman, W.C.; Francis, B.E., Rzeszotarski, W.J.; Gibson, R.E.; Jagoda, E.M.; Reba, R.C. Synthesis and evaluation of (17,20E)-21-[125I]iodo-19-norpregna-1,3,5 (10),20-tetraene-3,17- diol and of (17,20E)-21-[125I]iodo-11-methoxy-19-norpregna-1,3,5(10),20- tetraene-3,17-diol (17-(iodovinyl)estradiol Derivatives) as high specific activity potential radiopharmaceuticals. J. Med. Chem., 1984, 27, 1287-1291. (Pubitemid 14032240)
212. Jagoda, E.M.; Gibson, R.E.; Goodgold, M.; Ferreira, N.; Francis, B.E.; Reba, R.C.; Rzeszotarski, W.J.; Eckelman, W.C. [I-125] 17-iodovinyl 11-methoxyestradiol: in vivo and in vitro properties of a high-Affinity estrogenreceptor radiopharmaceutical. J. Nucl. Med., 1984, 25, 472-477. (Pubitemid 14131973)
213. McManaway, M.E.; Jagoda, E.M.; Kasid, A.; Eckelman, W.C.; Francis, B.E.; Larson, S.M.; Gibson, R.E.; Reba, R.C.; Lippman, M.E. [125I]17-iodovinyl-11- methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the vras H oncogene. Cancer Res., 1987, 47, 2945-2949. (Pubitemid 17113440)
214. Hanson, R.N.; Herman, L.W.; Fiaschi, R.; Napolitano, E. Stereochemical probes for the estrogen receptor: synthesis and receptor binding of (17,20E/Z)-21-phenyl-19-norpregna-1,3,5(10),20-tetraene-3,17-diols. Steroids, 1996, 61, 718-722. (Pubitemid 27031007)
215. Hochberg, R.B.; Rosner, W. Interaction of 16-[125I]iodo-estradiol with estrogen receptor and other steroid-binding proteins. Proc. Natl. Acad. Sci. USA, 1980, 77, 328-332. (Pubitemid 10126040)
216. Hochberg, R.B.; Zielinki, J.E.; Duaux, W.L.; Strong, P. The molecular structure of 16-iodo-17-estradiol, a high affinity ligand for the estrogen receptor. J. Steroid Biochem., 1986, 25, 615-618. (Pubitemid 17202563)
217. Fevig, T.L.; Mao, M.K.; Katzenellenbogen, J.A. Estrogen receptor binding tolerance of 16-substituted estradiol derivatives. Steroids, 1988, 51, 471-497. (Pubitemid 19037843)
218. VanBrocklin, H.F.; Liu, A.; Welch, M.J.; O'Neil, J.P.; Katzenellenbogen, J.A. The synthesis of 7-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids, 1994, 59, 34-45.
219. Bohl, M.; Schubert, G.; Koch, M.; Reck, G.; Strecke, J.; Wunderwald, M.; Prousa, R.; Ponsold, K. Quantitative structure-Activity relationships of estrogenic steroids substituted at C14, C15. J. Steroid Biochem., 1987, 26, 589-597. (Pubitemid 17066993)
220. Gantchev, T. G.; Ali, H.; van Lier, J E. Quantitative structure-Activity relationships/ comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halogenated estradiol derivatives. J. Med. Chem., 1994, 37, 4164-4175
221. Lee, D.L; Kollman, P.A.; Marsh, F.J.; Wolff, M.E. Quantitative relations between steroid structure and binding to putative progesterone receptors. J. Med. Chem., 1977, 20, 1139-1146. (Pubitemid 8170471)
222. Seeley, D.H.; Wang, W-Y.; Salhanick H.A. Molecular Interactions of Progesterone Analogues with Rabbit Uterine Cytoplasmic Receptor. J. Biol. Chem., 1982, 257, 13359-13366. (Pubitemid 13188951)
223. Bohl, M; Simon, Z; Vlad, A; Kaufmann, G; Ponsold, K. MTD calculations on quantitative structure-Activity relationships of steroids binding to the progesterone receptor. Z. Naturforschg. C., 1987, 42, 935-40.
224. Duax, W.L.; Griffin, J.F.; Rohrer, D.C. Steroid conformation, receptor binding, and hormone action. In: Horn A.S., Ed. X-ray crystallography and drug action: The ninth course of the International School of Crystallography. U.K., Oxford University Press, 1984, pp. 406-426.
225. Raynaud, J.P.; Ojasoo, T.; Bouton, M.M.; Philibert, D. Receptor binding as a tool in the development of new bioactive steroids. In:Drug design. New York: Academic Press; 1979, Vol 8, 170-214.
226. Ogle, T.F.; Beyer, B.K. Steroid-binding specificity of the progesterone receptor from rat placenta. J. Steroid Biochem., 1982, 16, 147-150. (Pubitemid 12119912)
227. Kontula, K.; Jännea, O.; Luukkainena, T.; Vihko, R. Progesterone-binding protein in human myometrium. Ligand specificity and some physicochemical characteristics. Biochim. Biophys. Acta, 1973, 328, 145-153.
228. Smith, H.E.; Smith, R.G.; Toft, D.O.; Neergaard, J.R.; Burrows, E.P.; O'Malley, B.W. Binding of Steroids to Progesterone Receptor Proteins in Chick Oviduct and Human Uterus. J. Biol. Chem., 1974, 249, 5924-5932.
229. Westphal, U. Bindung von Progesteron und anderen Steroid-hormonen an Proteine des Blutserums. Hoppe Seyler's Z. Physiol. Chem., 1978, 359, 431-447. (Pubitemid 9123103)
230. Duax, W.L.; Cody, V.; Griffin, J.F.; Rohrer, D.C.; Weeks, C.M. Molecular conformation and protein binding affinity of progestins. J. Toxicol. Environ. Health., 1978, 4, 205-227. (Pubitemid 8352958)
231. Glusker, J.P. Structural aspects of steroid hormones and carcinogenic polycyclic aromatic hydrocarbons. In: Litwack, G., Ed. Biochemical Actions of Hormones, New York, Academic Press, 1979, Vol 6, pp. 121-204.
232. Janne, O.; Kontula, K.; Vihko, R. Progestin receptors in human tissues: concentrations and binding kinetics. J. Steroid Biochem., 1976, 7, 1061-1068. (Pubitemid 8051687)
233. Raynaud, J.P.; Ojasoo, T. Promegeston, a new progestin. J. Gynecol. Obstet. Biol. Reprod. (Paris), 1983, 12, 697-710.
234. Zeelen, F.J.; van den Broek, A.J. Synthesis of 16-ethyl-21-hydroxy-19- norpregn-4-ene-3,20-dione (Org 2058). Rec. Trav. Chim. des Pays-Bas, 1985, 104, 239-242.
235. Sharoni, Y.; Feldman, B.; Karny, N.; Levy, J. ORG-2058 as a ligand in the assay of progesterone receptor in breast cancer. Steroids, 1986, 48, 419-426. (Pubitemid 18048927)
236. Horwitz, K.B.; McGuire, W.L. Estrogen control of progesterone receptor in human breast cancer. J. Biol. Chem., 1978, 253, 2223-2228.
237. Horwitz, K.B. The structure and function of progesterone receptors in breast cancer. J. Steroid Biochem., 1987, 27, 447-457. (Pubitemid 18059249)
238. Namer, M.; Lalanne, C.; Baulieu, E.E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res., 1980, 40, 1750-1752. (Pubitemid 10102027)
239. Howell, A.; Harland, R.N.L.; Barnes, D.M.; Baildam, A.D.; Wilkinson, M.J.S.; Hayward, E.; Swindell, R. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res., 1987, 47, 300-304. (Pubitemid 17002140)
240. Noguchi, S.; Muiyauchi, K.; Nishizawa, Y.; Koyama, H. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time. Cancer, 1988, 61, 1345-1349. (Pubitemid 18076407)
241. Gelbfish, G.A.; Davison, A.L.; Kopel, S.; Schreibmen, B.; Gelbfish, J.S.; Degenshein, G.A., Herz, B.L.; Cunningham, J.N. Relationship of Estrogen and Progesterone Receptors to Prognosis in Breast Cancer. Ann. Surg., 1988, 207, 75-79. (Pubitemid 18057276)
242. Santen, R.; Manni, A.; Harvey, H.; Redmond, C. Endocrine treatment of breast cancer in women. Endocrine Rev., 1990, 11, 221-265. (Pubitemid 20182870)
243. Cui, X.; Schiff, R.; Arpino, G.; Osborne, C.K.; Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol., 2005, 23, 7721-7735. (Pubitemid 46291836)
244. Osborne, C.K.; Schiff, R.; Arpino, G; Lee, A.S.; Hilsenbeck, V.G. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast, 2005, 14, 458-465. (Pubitemid 41683567)
245. Furr, B.J.A.; Jordan, V.C. The Pharmacology and Clinical Uses of Tamoxifen. Pharmacol. Ther., 1984, 25, 127-205. (Pubitemid 14015738)
246. Lim, J.L.; Zheng, L.; Berridge, M.S.; Tewson, T.J. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl. Med. Biol., 1996, 23, 911-915. (Pubitemid 26392233)
247. Romer, J.; Fuchtner, F.; Steinbach, J.; Johanssen, B. Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging. Nucl. Med. Biol., 1999, 26, 473-479. (Pubitemid 29254036)
248. Sasaki, M.; Fukumura, T.; Kuwabara, Y.; Yoshida, T.; Nakagawa, M.; Ichiya, Y.; Masuda, K. Biodistribution and breast tumor uptake of 16alpha- [18F]-fluoro-17beta-estradiol in rat. Ann. Nucl. Med., 2000, 14, 127-130. (Pubitemid 30317966)
249. Seimbille, Y.; Rousseau, J.; Benard, F.; Morin, C.; Ali, H.; Avvakumov, G.; Hammond, G.L.; van Lier, J.E. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids, 2002, 67, 765-775. (Pubitemid 34765665)
250. Aliaga, A.; Rousseau, J.; Ouellette, R.; Cadorette, J.; van Lier, J.E.; Lecomte, R.; Benard, F. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl. Med. Biol., 2004, 31, 761-770. (Pubitemid 38887758)
251. Yoo, J.; Dence, C.S.; Sharp, T.L.; Katzenellenbogen, J.A.; Welch, M.J. Synthesis of an estrogen receptor-selective radioligand: 5-[18F]fluoro-(2R,3S)- 2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16-[18F]Fluoro-17-estradiol. J. Med. Chem., 2005, 48, 6366-6378. (Pubitemid 41428988)
252. Moresco, R.M.; Casati, R.; Lucignani, G.; Carpinelli, A.; Schmidt, K.; Todde, S.; Colombo, F.; Fazio, F. Systemic and cerebral kinetics of 16- [18F]fluoro-17-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J. Cereb. Blood Flow Metabol.,1995, 15, 301-311.
253. Katzenellenbogen, J.A.; Mathias, C.J.; Vanbrocklin, H.F.; Brodack, J.W.; Welch, M.J. Titration of the in vivo uptake of 16-[18F]fluorestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptorbinding radiopharmaceutical development. Nucl. Med. Biol., 1993, 20, 735-745. (Pubitemid 23233467)
254. Dehdashti, F.; Mortimer, J.E.; Siegel, B.A.; Griffeth, L.K.; Bonasera, T.J.; Fusselman, M.J.; Detert, D.D.; Cutler, P.D.; Katzenellenbogen, J.A.; Welch, M.J. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J. Nucl. Med., 1995, 36, 1766-1774.
255. Mortimer, J.E.; Dehdashti, F.; Siegel, B.A.; Katzenellenbogen, J.A.; Fracasso, P.; Welch, M.J. Positron emission tomography with 2-[18F]fluoro-2- deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin. Cancer Res., 1996, 2, 933-939.
256. Linden, H.M.; Stekhova, S.A.; Link, J.M.; Gralow, J.R.; Livingston, R.B.; Ellis G.K.; Petra, P.; Peterson, L.M.; Schubert, E.; Dunnwald, L.K.; Krohn, K.A.; Mankoff, D.A. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol., 2006, 24, 2793-2799. (Pubitemid 46630578)
257. Mankoff, D.A.; Peterson, L.M.; Tewson, T.J.; Link, J.M.; Gralow, J.R.; Graham, M.M.; Krohn, K.A. [18F]Fluoroestradiol Radiation Dosimetry in Human PET Studies. J. Nucl. Med., 2001; 42, 679-684. (Pubitemid 32298291)
258. Mathias, C.J.; Welch, M.J.; Katzenellenbogen, J.A.; Brodack, J.W.; Kilbourn M.R.; Carlson K.E.; Kiesewetter, D.O. Characterization of the uptake of 16a-([18F]fluoro)-17b-estradiol in DMBA-induced mammary tumor. Nucl. Med. Biol., 1987, 14, 15-25. (Pubitemid 17030178)
259. Mankoff, D.A.; Tewson, T.J.; Eary, J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alphafluoroestradiol (FES). Nucl. Med. Biol., 1997, 24, 341-348. (Pubitemid 27294677)
260. ClinicalTrials.gov. NCT00602043: F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer. http://clinicaltrials. gov/ct2/show/NCT00602043 (Accessed August 7, 2012).
261. VanBrocklin, H.F.; Pomper, M.G.; Carlson, K.E.; Welch, M.J.; Katzenellenbogen, J.A. Preparation and evaluation of 17-ethynyl-substituted 16-[18F] Fluoroestradiols: selective receptor-based PET imaging agents. Nucl. Med. Biol., 1992, 19, 363-374.
262. Raynaud, J.P., Bouton, M.M., Bourquin, D.G., Philibert, C.T., Boulanger, G.A. Comparative study of estrogen action. Mol. Pharmacol., 1973, 9, 520-523.
263. Raynaud, J.P.; Martin, P.M.; Bouton, M.-M.; Ojasoo, T. 11-Methoxy-17-ethynyl-1,3,5(10)-estratriene 3,17-diol (Moxestrol), a Tag for Estrogen Receptor Binding Sites in Human Tissues. Cancer Res., 1978, 38, 3044-3050. (Pubitemid 9001411)
264. Bélanger, A.; Philibert, D.; Teutsch, G. Regio and stereospecific synthesis of 11-substituted 19-norsteroids: Influence of 11-substitution on progesterone receptor affinity -(1). Steroids, 1981, 37, 361-382. (Pubitemid 11078109)
265. Katzenellenbogen, J.A.; McElvany, K.D.; Senderoff, S.G.; Carlson, K.E.; Landvatter, S.W.; Welch, M.J. 16-[77Br]bromo-11-methoxyestradiol-17: a gamma-emitting estrogen imaging agent with high uptake and retention by target organs. J. Nucl. Med., 1982, 23, 411-419. (Pubitemid 12084788)
266. Feenstra, A.; Nolten, G.M.J.; Vaalburg, W.; Reiffers, S.; Woldring, M.G. Radiotracers binding to estrogen receptors: I. Tissue distribution of 17-ethynylestradiol and moxestrol in normal and tumor bearing rats J. Nucl. Med., 1982, 23, 599-605. (Pubitemid 12090916)
267. Hanson, R.N.; Franke, L.A. Preparation and evaluation of 17-[125I]Iodovinyl-11-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication. J. Nucl. Med., 1984, 25, 998-1002. (Pubitemid 14033044)
268. Zielinski, J.E.; Yabuki, H.; Pahuja, S.L.; Larner, J.M.; Hochberg, R.B. 16-[125I]iodo-11-methoxy-17-estradiol: a radichemical probe for estrogensensitive tissues. Endocrinology, 1986, 119, 130-139. (Pubitemid 16100718)
269. VanBrocklin, H.F.; Rocque, P.A.; Lee, H.V.; Katzenellenbogen, J.A.; Welch, M.J. 16-[18F]Fluoromoxestrol: A potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumours. Life Sci., 1993, 53, 811-819.
270. Katzenellenbogen, J.A.; Carlson, K.E.; Heiman, D.F.; Goswami, R. Receptor-binding radiopharmaceuticals for imaging breast tumors: estrogenreceptor interactions and selectivity of tissue uptake of halogenated estrogen analogs. J. Nucl. Med., 1980, 21, 550-558. (Pubitemid 10116904)
271. Jonson, S.D.; Bonasera, T.A.; Dehdashti, F.; Cristel, M.E.; Katzenellenbogen, J.A.; Welch, M.J. Comparative breast tumor imaging and comparative in vitro metabolism of 16-[18F]fluoroestradiol-17and 16-[18F] fluoromoxestrol in isolated hepatocytes. Nucl. Med. Biol., 1999, 26, 123-130. (Pubitemid 29030532)
272. McElvany, K.D.; Carlson, K.E.; Katzenellenbogen, J.A.; Welch, M.J. Factors affecting the target site uptake selectivity of estrogen radipharmaceuticals: serum binding and endogeneous steroids. J. Steroid Biochem., 1983, 18, 635-641. (Pubitemid 13069616)
273. Hobbs, C.J.; Jones, R.T.; Plymate, S.R. The effects of sex hormone binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid. J. Steroid Biochem., 1992, 42, 629-635.
274. Fortunati, N.; Fissore, F.; Fazzari, A.; Berta, L.; Benedusi-Pagliano, E.; Frairia, R. Biological relevance of the interaction between sex steroid binding protein and its specific receptor of MCF-/ cells: Effect on the estradiolinduced cell proliferation. J. Steroid Biochem., 1993, 45, 435-444. (Pubitemid 23163020)
275. Fortunati, N.; Fissore, F.; Comba, A.; Becchis, M.; Catalano, M.G.; Fazzari, A.; Berta, L.; Frairia, R. Sex steroid-binding protein and its membrane receptor in estrogen-dependent breast cancer: biological and pathophysiological impact. Horm. Res., 1996, 45, 202-206. (Pubitemid 26079709)
276. Bonasera, T.A.; Dehdashti, F.; Welch, M.J.; Katzenellenbogen, J.A. Comparasion of the hepatic metabolism of 16-[18F]fluoroestradiol (FES) and 16-[18F]fluoromoxestrol (FMOX) utilizing isolated hepatocytes from different species. J. Nucl. Med., 1993, 34, 49P-49P.
277. Morgan, P.; Maggs, J.L; Bulman-Page, P.C.; Hussain, F.; Park, B.K. The metabolism of 2-And 4-fluoro-17-oestradiol in the rat and its implications for oestrogen carcinogenesis. Biochem. Pharmacol., 1992, 43, 985-993.
278. Bénard, F.; Ahmed, N.; Beauregard, J.M.; Rousseau, J.; Aliaga, A.; Dubuc, C.; Croteau, E.; van Lier, J.E. Biodistribution of fluorinated estradiol derivatives in ER + tumor-bearing mice: impact of substituents, formulation and specific activity. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35, 1473-1479
279. Turcotte, E.; Paquette, M.; Lavallée, Eric.; Langlois, R.; Dubreuil, S.; Senta, H.; Lecomte, R.; Guerin, B.; Benard, F.; Van Lier, J. Comparison of 4FMFES-PET with FES-PET in a phase II trial to detect estrogen receptorpositive breast cancer: Preliminary results. J Nucl Med. 2012, 53 (S1), 281
280. Ali, H.; Rousseau, J.; Ghaffari, M.A.; van Lier, J.E. Synthesis, receptor binding, and tissue distribution of 7-And 11-substituted (17,20E)-And (17,20Z)-21-[125I]Iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-diols. J. Med. Chem. 1991, 34, 854-860.
281. VanBrocklin, H.F.; Liu, A.; Welch, M.J.; O'Neil, J.P.; Katzenellenbogen, J.A. The synthesis of 7-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids, 1994, 59, 34-45.
282. Pomper, M.G.; Katzenellenbogen, J.A.; Thomas, R.D.; Mathias, C.J.; Van-Brocklin, H.; Welch, M.J. Fluorine-18 labeled 11-substituted estrogens: synthesis, receptor binding, and comparative target tissue uptake studies. J. Labelled Comp. Radiopharm., 1989, 26, 323-325.
283. Hanson, R.N.; Franke, L.A.; Kaplan, M.L. Synthesis and evaluation of (17,20E)21-[125I]Iodo-11-substituted-19-norpregna-1,3,5(10)-tetraene-3,17-diols: the influence of 11-stereochemistry on tissue distribution of radioiodinated estrogens. J. Nucl. Med., 1989, 16, 3-9. (Pubitemid 19032539)
284. Hanson, R.N.; Napolitano, E.; Fiaschi, R.; Onan, K.D. Synthesis and estrogen receptor binding of novel 11-substituted estra-1,3,5(10)-triene-3,17- diols. J. Med. Chem., 1990, 33, 3155-3160.
285. French, A.N.; Napolitano, E.; VanBrocklin H.F.; Hanson, R.N.; Welch, M.J.; Katzenellenbogen, J.A. Synthesis, radiolabeing and tissue distribution of 11-fluoroalkyl-And 11-fluoroalkoxy-substituted estrogens: target tissue uptake selectivity and defluorination of a homologous series of fluorine-18-labeled estrogens. Nucl. Med. Biol., 1993, 20, 31-47. (Pubitemid 23024062)
286. Seimbille, Y.; Bénard, F.; van Lier, J.E. Synthesis of 16alpha-fluoroICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J. Chem. Soc., Perkin Trans I, 2002, 20, 2275-2281. (Pubitemid 35327407)
287. Seimbille, Y.; Bénard, F.; Rousseau, J.; Pépin, E.; Aliaga, A.; Tessier, G.; van Lier, J.E. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16-Alpha position of fulvestrant (Faslodex; ICI 182,780). Nucl. Med. Biol., 2004, 31, 691-698. (Pubitemid 38887750)
288. Parisot, J.P; Hu, X.F.; Sutherland, R.L.; Wakeling, W, Zalcberg, J.R.; De-Luise, M. The pure antiestrogen ICI 182,780 binds to a high-Affinity site distinct from the estrogen receptor. Int. J. Cancer., 1995; 62, 480-484.
289. Yang, D.J.; Tewson, T.; Tansey, W.; Kuang, L.-R.; Reger, G.; Cherif, A.; Wright, K.C.; Moult, R.G.; Tilbury, R.S.; Chu, K.; Kim, E.E.; Wallace, S. Halogenated Analogs of Tamoxifen -Synthesis, Receptor Assay, and Inhibition of MCF7-Cells. J. Pharmaceut. Sci., 1992, 81, 622-625.
290. Yang, D.; Kuang, L.R.; Cherif, A.; Tansey, W.; Chun, L.; Lin, W.J.; Wei, L.C.; Kim, E.E.; Wallace, S. Synthesis of [18F]fluoroalanine and [18F] fluorotamoxifen for imaging breast tumors. J. Drug Target., 1993, 1, 259-267. (Pubitemid 2027464)
291. Inoue, T.; Kim, E.E.; Wallace, S.; Yang, D.J.; Wong, F.C.; Bassa, P.; Cherif, A.; Delpassand, E.; Buzdar, A.; Podoloff, D.A. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother. Radiopharm., 1996, 11, 235-245. (Pubitemid 26313530)
292. McElvany, K.D.; Carlson, K.E.; Welch, M.J.; Senderoff, S.G.; Katzenellenbogen, J.A. In vivo comparasion of 16-[77Br]Bromoestradiol-17and 16-[125I]Iodoestradiol-17. J. Nucl. Med., 1982, 23, 420-424.
293. McElvany, K.D; Katzenellenbogen, J.A.; Shaffer, B.A; Siegel, K.E; Senderoff, S.G.; Welch, M.J. 16-[77Br]-bromoestradiol-17: Dosimetry and Preliminary Clinical Studies. J. Nucl. Med., 1982, 23, 425-430. (Pubitemid 12084790)
294. Senderoff, S.G.; McElvany, K.D.; Carlson, K.E.; Heiman, D.F.,; Katzenellenbogen, J.A.; Welch, M.J. Methodology for the synthesis and specific activity determination of 16-[77Br]-bromoestradiol-17and 16-[77Br]-bromo-11- methoxyestradiol-17, two estrogen receptor-binding radiopharmaceuticals. Appl. Radiat. Isotop., 1982, 33, 545-551. (Pubitemid 12027499)
295. Katzenellenbogen, J.A.; Senderoff, S.G.; McElvany, K.D.; O'Brien, H.A.Jr.; Welch, M.J. 16-[Bromine-77]-bromoestradiol-17: a high specific-Activity, gamma-emitting tracer with uptake in rat uterus and induced mammary tumors. J. Nucl. Med., 1981, 22, 42-47. (Pubitemid 11213144)
296. Vaalburg, W.; Reiffers, S.; Beerling, E.; Pratt, J.J.; Woldring, M.G.; Wynberg, H. The preparation of carbon-11 labeled 17-ethynylestradiol. J. Labelled Comp. Radiopharm., 1977, 13, 200-201.
297. Vaalburg, W.; Feenstra, A.; Wiegman, T. Carbon-11 labeled moxestrol and 17-methyl estradiol as receptor binding radiopharmaceuticals. J. Labelled Comp. Radiopharm., 1980, 18, 100-101. (Pubitemid 11158193)
298. Napolitano, E.; Fiaschi, R.; Carlson, K.E.; Katzenellenbogen, J.A. 11-Substituted estradiol derivatives, potential high-Affinity carbon-11 labeled probes for the estrogen receptor: A structure-Affinity relationship study. J. Med. Chem., 1995, 38, 429-434
299. Reiffers, S.; Vaalburg, W.; Wiegman, T.; Wynberg, H.; Woldring, M.G. Carbon-11 labelled methyllithium as methyl donating agent: The addition to
300. Feenstra, A.; Vaalburg, W.; Nolten, G.M.J.; Reiffers, S.; Talma, A.G.; Wiegman, T.; van der Molen, H.D.; Woldring, M.G. Estrogen receptor binding pharmaceuticals: II. Tissue distribution of 17-methylestradiol in normal and tumor bearing rats. J. Nucl. Med., 1983, 24, 522-528. (Pubitemid 13034539)
301. Napolitano, E.; Dence, C.S.; Welch, M.J.; Katzenellenbogen, J.A. Carbon-11 labeled estrogens as imaging agents for breast tumors. J. Nucl. Med., 1994, 35S, 250P.
302. Dence, C.S.; Napolitano, E.; Katzenellenbogen, J.A.; Welch, M.J. Carbon-11-labeled estrogens as potential imaging agents for breast tumors. Nucl. Med. Biol. 1996, 23, 491-496. (Pubitemid 26233221)
303. Wust, F.; Zessin J.; Johannsen, B. A new approach for 11C-C bond formation: synthesis of 17-(3'-[11C]prop-1-yn-1-yl)-3-methoxy-3,17-estradiol. J. Label. Compd. Radiopharm., 2003, 46, 333-342. (Pubitemid 36514055)
304. Kochanny, M.J.; VanBrocklin, H.F.; Kym, P.R.; Carlson, K.E.; O'Neil, J.P.; Bonasera, T.A.; Welch, M.J.; Katzenellenbogen, J.A. Fluorine-18-labeled progestin ketals: Synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J. Med. Chem., 1993, 36, 1220-1127.
305. Carlson, K.E.; Brandes, S.J.; Pomper, M.G.; Katzenellenbogen, J.A. (1988). Uptake of three [3H]progestins by target tissue in vivo: implications for the design of diagnostic imaging agents. Nucl. Med. Biol. 15:403-408.
306. Buckman, B.O.; Bonasera, T.A.; Kirschbaum, K.S.; Welch, M.J.; Katzenellenbogen, J.A. Fluorine-18-labeled progestin 16,17-dioxolanes: development of high-Affinity ligands for the progesterone receptor with high in vivo target site selectivity. J. Med. Chem. 1995, 38, 328-337.
307. Fried, J.; Sabo, E.F.; Grabowich, P.; Lerner, L.J.; Kessler, W.B.; Brennan, D.M.; Borman, A. Progestationally active acetals and ketals of 16,17-dihydroxyprogesterone. Chem. Ind., 1961, 465-466.
308. Lerner, L.J.; Brennan, D.M.; Borman, A. Biological Activities of 16,17-dihydroxyprogesterone derivatives. Proc. Soc Exp. Biol. Med., 1961, 106, 231-234.
309. Kilbourn, M.J.; Carey, J.E.; Koeppe, R.A.; Haka, M.S.; Hutchins, G.D.; Sherman, P.S.; Kuhl, D.E. Biodistribution, dosimetry. metabolism and monkey PET studies of [18F]IGBR13119. Imaging the dopamine uptake system in vivo. Nucl. Med. Biol., 1989, 16, 569-576. (Pubitemid 19237456)
310. Plenevaux, A.; Fowler, J.S.; Dewey, S.L.; Wolf, A.P.; Guillaume, M. The synthesis of no-carrier added DL-4[18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction. Appl. Radiat. Isotop., 1991, 42, 121-127.
311. Kym, P.R.; Carlson, K.E.; Katzenellenbogen, J.A. Progestin 16,17-dioxolane ketals as molecular probes for the progesterone receptor: Synthesis, binding affinity and photochemical evaluation. J. Med. Chem., 1993, 36, 1111-1119. (Pubitemid 23159284)
312. Cooke, B.A.; Vallance, D.K. Metabolism of megestrol acetate and related progesterone analogues by liver preparations in vitro. Biochem. J., 1965, 97, 672-677.
313. Fensome A.; Bender, R.; Chopra, R.; Cohen, J.; Collins, M.A.; Hudak, V.; Malakian, K.; Lockhead, S.; Olland, A.; Svenson, K.; Terefenko, E.A.; Unwalla, R.J.; Wilhelm, J.M.; Wolfrom, S.; Zhu, Y.; Zhang, Z.; Zhang, P.; Winneker, R.C.; Wrobel, J. Synthesis and structure-Activity relationship of novel 6-Aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist Tanaproget. J. Med. Chem., 2005, 48, 5092-5095. (Pubitemid 41113894)
314. Zhou, H.-B.; Lee, J.H.; Mayne, C.G.; Carlson, K.E.; Katzenellenbogen, J.A. Imaging progesterone receptor in breast tumors: Synthesis and receptor binding affinity of fluoroalkyl-substituted analogs of Tanaproget. J. Med. Chem., 2010, 53, 3349-3360.
315. Lee, J.H.; Zhou, H.-B.; Dence, C.S.; Carlson, K.E.; Welch, M.J.; Katzenellenbogen, J.A. Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjugate Chem., 2010, 21, 1096-1104.
316. Choe, Y.S.; Bonasera, T.A.; Chi, D.Y.; Welch, M.J.; Katzenellenbogen, J.A. 6-[18F]Fluoroprogesterone: Synthesis via halofluorination-oxidation, receptor binding and tissue distribution. Nucl. Med. Biol. 1995, 22, 635-642.
317. DeSombre, E.R.; Mease, R.C.; Hughes, A.; Harper, P.V.; DeJesus, O.T.; Friedman, A.M. Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res., 1988, 48, 899-906. (Pubitemid 18061884)
318. DeSombre, E.R.; Shafii, B.; Hanson, R.N.; Kuivanen, P.C.; Hughes, A. Estrogen receptor directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res., 1992, 52, 5752-5758.
319. Kassis, A.I.; Adelstein, S.J.; Haydock, C.; Sastry, K.S.R.; McElvany, K.D.; Welch, M.J. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat. Res., 1982, 90, 362-373. (Pubitemid 12157053)
320. Zhou, D.; Carlson, K.E.; Katzenellenbogen, J.A.; Welch, M.J. Bromine-And iodine-substituted 16,17-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J. Med. Chem., 2006, 49, 4737-4744. (Pubitemid 44162701)